Cited by 711SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingAnimal Virus Infections Studies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Open access

Nie, Jianhui, Li, Qianqian, Wu, Jiajing, Zhao, Chenyan, Hao, Huan, Liu, Huan, Zhang, Li, Nie, Lingling, Qin, Haiyang, Wang, Meng, Lu, Qiong, Li, Xiaoyu, Sun, Qiyu, Liu, Junkai, Fan, Changfa, Huang, Weijin, Xu, Miao, Wang, Youchun·2020·Emerging Microbes & Infections

DOI 10.1080/22221751.2020.1743767PMC PMC7144318

Open this paper in CoChat — free account

Abstract

Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/22221751.2020.1743767

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Verification of the incorporaiton of SARS-CoV-2 spike protein in the pseudovirus. The surface proteins of the particle were investigated using western blotting (A), from left to right lane showing VSV pseudovirus, medium control and SARS-CoV-2 pseudovirus. The VSV pseudotyped virus and cell culture medium were prepared with the same procedure and used as negative control and pseudovirus negative control. The SARS-CoV-2 pseudovirus, together with G*ΔG-VSV, were tested against VSV G specific antibody (B).CC BY · PubMed Central

Figure 2. Selection of the cell line. Six types of cells were tested for VSV (A), and SARS-CoV-2 (B) pseudoviruses. The y-axis showed the absolute RLU value detected 24 h after pseudovirus infection. Cell backgrounds without pseudovirus infection were shown in figure C.CC BY · PubMed Central

Figure 3. Optimization of cell numbers for neutralization. (A) Effect of cells numbers on the titration of pseudovirus. The y-axis showed the RLU fold over the cell background. (B) Effect of cells numbers on the neutralization. Cell numbers and corresponding R2 values were list in the tables. A serum sample from a healthy individual was tested as negative control shown in black lines and symbols.CC BY · PubMed Central

Figure 4. Optimization of virus dose for neutralization. The viral inocula with a dose range starting from 41 to 1300 TCID50/well were tested for SARS-CoV-2 PBNA. A serum sample from a healthy individual was tested as negative control shown in black lines and symbols.CC BY · PubMed Central

Figure 5. Validation of the SARS-CoV-2 PBNA. (A) Specificity of the PBNA. A negative sample panel of seventy-four human and forty-six mouse serum samples were used to determine the specificity of this assay. (B) Inhibition curves for two SARS-CoV-2 convalescent patient serum samples and two negative serum samples derived from human and mouse. Typical four-parameter inhibition curves were observed for these two samples between log-transformed dilution and inhibition rate. The initial dilutions for positive and negative samples were 1:30 and 1:10 respectively, followed by 3-fold serial dilution. (C) Linear range for the PBNA. When the inhibition rate is in the range of 20%–80%, there is a linear relationship between the readout of the test sample and its dilution. (D) Reproducibility of the PBNA. A mixture of two SARS-CoV-2 coalescent patient serum samples was tested a total of 18 times on individual plates in three independent runs.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Self-citation
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citation
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citation
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China
Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,386
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
The Novel Coronavirus Originating in Wuhan, China
Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210
Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines
Whitt, M. A. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.08.006 · Cited by 431

Show all 27 references

Sorted by citations

Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J., Du, P. F., Wei, D., Yang, Z., Sun, X., Gong, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00426-x · Cited by 1,630
Self-citation
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Self-citation
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420
Self-citation
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225
Self-citation
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188
Self-citation
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
Tan, C. W., Chia, W. N., Qin, X., Liu, P., Chen, M. I.-C., Tiu, C. K., Hu, Z., Chen, V. C.-W., Young, B. E., Sia, W. R., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0631-z · Cited by 1,182
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
Ni, L., Ye, F., Cheng, M., Yu, F., Deng, Y., Zhao, H. J., Peng, W., Ge, J., Gou, M., Li, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.023 · Cited by 1,085
Self-citation
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L. R., Cheng, V. C., Edwards, K. M., Gandhi, R. T., Muller, W. J., O’Horo, J. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa478 · Cited by 1,045
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
Yang, H. J., Wang, W., Chen, Z., Lu, S., Yang, F., Bi, Z., Bao, L., Mo, F., Li, X., Huang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2599-8 · Cited by 767
Self-citation
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
Crawford, K. H. D., Eguia, R. T., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 744
Antibody tests for identification of current and past infection with SARS‐CoV‐2
Geppert, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P., Wickramasinghe, D., Bergman, H., Buckley, S. B., et al. (2022) · LSTM Online Archive (Liverpool School of Tropical Medicine) · Cited by 837
COVID-19 Neutralizing Antibodies Predict Disease Severity and Survival
García-Beltrán, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J. E., Hauser, B. M., Caradonna, T. M., Clayton, K., Nitido, A. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.12.015 · Cited by 708
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., Duyvesteyn, H. M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.005 · Cited by 687
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671
“RBD protein expressed frommRNA retained high affinity for recombinant human ACE2, as demonstrated by kinetics analysis using ForteBio Octet (Figure 1C), and functionally inhibited entry of a vesicular stomatitis virus (VSV)based pseudovirus expressing the SARS-CoV-2 S protein (Nie et al., 2020) in Huh7 cells (Figure 1…”
InfluentialSelf-citation
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
Antibody tests for identification of current and past infection with SARS-CoV-2
Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., di Ruffano, L. F., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652 · Cited by 649
A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids
Yang, L., Han, Y., Nilsson-Payant, B. E., Gupta, V., Wang, P., Duan, X., Tang, X., Zhu, J., Zhao, Z., Jaffré, F., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.06.015 · Cited by 645
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
Han, Y., Duan, X., Yang, L., Nilsson-Payant, B. E., Wang, P., Duan, F., Tang, X., Yaron, T. M., Zhang, T., Uhl, S., et al. (2021) · Nature · doi:10.1038/s41586-020-2901-9 · Cited by 530
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Zhao, M., Yang, W., Yang, F., Zhang, L., Huang, W., Hou, W., Fan, C., Jin, R., Feng, Y., Wang, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00558-8 · Cited by 536
Self-citation
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.035 · Cited by 482
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Whitman, J. D., Hiatt, J. B., Mowery, C. T., Shy, B. R., Yu, R., Yamamoto, T. N., Rathore, U., Goldgof, G. M., Whitty, C., Woo, J. M., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0659-0 · Cited by 455
Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2
Younes, N., Al‐Sadeq, D. W., Al-Jighefee, H. T., Younes, S. N., Al-Jamal, O., Daas, H. I., Yassine, H. M., & Nasrallah, G. K. (2020) · Viruses · doi:10.3390/v12060582 · Cited by 449
Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 427
Self-citation
Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection
Tali, S. H. S., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi‐Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 430
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.019 · Cited by 410
Self-citation
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110812 · Cited by 408
Molecular Diagnosis of COVID-19: Challenges and Research Needs
Feng, W., Newbigging, A. M., Le, C., Pang, B., Peng, H., Cao, Y., Wu, J., Abbas, G., Song, J., Wang, D., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02060 · Cited by 390
Self-citation
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
Lv, Z., Deng, Y., Ye, Q., Cao, L., Sun, C.-Y., Fan, C., Huang, W., Sun, S., Sun, Y., Zhu, L., et al. (2020) · Science · doi:10.1126/science.abc5881 · Cited by 364
Self-citation
The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
Zhang, L., Li, Q., Liang, Z., Li, T., Liu, S., Cui, Q., Nie, J., Wu, Q., Qu, X., Huang, W., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2017757 · Cited by 352
Self-citation
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
To, K. K., Sridhar, S., Chiu, K. H., Hung, D. L. L., Li, X., Hung, I. F., Tam, A. R., Chung, T. W., Chan, J. F., Zhang, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1898291 · Cited by 359
Self-citation
Coronavirus disease 2019 (COVID‐19): An overview of the immunopathology, serological diagnosis and management
Anka, A. U., Tahir, M. I., Abubakar, S. D., Alsabbagh, M. Y., Zian, Z., Hamedifar, H., Sabzevari, A., & Azizi, G. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12998 · Cited by 365
SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.042 · Cited by 346
Self-citation
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
Ai, J., Zhang, H., Zhang, Y., Lin, K., Zhang, Y., Wu, J., Wan, Y., Huang, Y., Song, J., Fu, Z., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2022440 · Cited by 339
Self-citation
COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at the Workplace
Cirrincione, L., Plescia, F., Ledda, C., Rapisarda, V., Martorana, D., Moldovan, R. E., Theodoridou, K., & Cannizzaro, E. (2020) · Sustainability · doi:10.3390/su12093603 · Cited by 349
Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen
Liu, D., Ju, C., Han, C., Shi, R., Chen, X., Duan, D., Yan, J., & Yan, X. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112817 · Cited by 329
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
Muruato, A. E., Fontes-Garfias, C. R., Ren, P., Garcia-Blanco, M. A., Menachery, V. D., Xie, X., & Shi, P.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17892-0 · Cited by 319
The Role of Antibody Testing for SARS-CoV-2: Is There One?
Theel, E. S., Slev, P. R., Wheeler, S., Couturier, M. R., Wong, S. J., & Kadkhoda, K. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00797-20 · Cited by 314
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
Trougakos, I. P., Stamatelopoulos, K. S., Terpos, E., Tsitsilonis, O., Aivalioti, E., Paraskevis, D. N., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-020-00703-5 · Cited by 305
The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review
Haghani, M., Bliemer, M. C. J., Goerlandt, F., & Li, J. (2020) · Safety Science · doi:10.1016/j.ssci.2020.104806 · Cited by 274
ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection
Hachim, A., Kavian, N., Cohen, C. A., Chin, A. W. H., Chu, D. K. W., Mok, C. K. P., Tsang, O. T., Yeung, Y. C., Perera, R. A. P. M., Poon, L. L. M., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0773-7 · Cited by 270
Humoral Responses and Serological Assays in SARS-CoV-2 Infections
Galipeau, Y., Greig, M., Liu, C., Driedger, M., & Langlois, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610688 · Cited by 247
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
Du, S., Cao, Y., Zhu, Q., Yü, P., Qi, F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.035 · Cited by 238
Self-citation
Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis
Liu, M., Gao, Y., Yuan, Y., Yang, K., Shi, S., Zhang, J., & Tian, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104896 · Cited by 230
COVID-19 Antibody Tests and Their Limitations
Liu, G., & Rusling, J. F. (2021) · ACS Sensors · doi:10.1021/acssensors.0c02621 · Cited by 226
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Xie, X., Muruato, A. E., Zhang, X., Lokugamage, K. G., Fontes-Garfias, C. R., Zou, J., Liu, J., Ren, P., Balakrishnan, M., Cihlář, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19055-7 · Cited by 216
Self-citation
SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself
Ferreira‐Gomes, M., Kruglov, A., Durek, P., Heinrich, F., Tizian, C., Heinz, G. A., Reguant, A. P., Du, W., Mothes, R., Fan, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22210-3 · Cited by 216
Self-citation
A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
Dieterle, M. E., Haslwanter, D., Bortz, R. H., Wirchnianski, A. S., Lasso, G., Vergnolle, O., Abbasi, S. A., Fels, J. M., Laudermilch, E., Florez, C., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.020 · Cited by 206
Antibody tests for identification of current and past infection with SARS-CoV-2
Fox, T., Geppert, J., Dinnes, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P. N., Wickramasinghe, D., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652.pub2 · Cited by 205
High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients
Chen, Y., Tong, X., Wang, J., Huang, W., Yin, S., Huang, R., Yang, H., Chen, Y., Huang, A., Liu, Y., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.067 · Cited by 199
Self-citation
Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges
Kiliç, T., Weissleder, R., & Lee, H. (2020) · iScience · doi:10.1016/j.isci.2020.101406 · Cited by 199
The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
Hu, Y., Meng, X., Zhang, F., Xiang, Y., & Wang, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1888660 · Cited by 183
Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection
Guo, L., Yao, Z., Yang, L., Zhang, H., Qi, Y., Gou, L., Wang, X., Liu, D., Zhang, L., Cheng, Y., et al. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.127742 · Cited by 182
Self-citation
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
Perkmann, T., Perkmann‐Nagele, N., Köller, T., Mucher, P., Radakovics, A., Marculescu, R., Wolzt, M., Wagner, O. F., Binder, C. J., & Haslacher, H. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00247-21 · Cited by 185
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses
Ladner, J. T., Henson, S. N., Boyle, A. S., Engelbrektson, A. L., Fink, Z., Rahee, F., D’ambrozio, J., Schaecher, K. E., Stone, M., Dong, W., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100189 · Cited by 186
Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System
Xu, R., Shi, M., Li, J., Song, P., & Li, N. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00862 · Cited by 176
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
Rockett, R. J., Basile, K., Maddocks, S., Fong, W., Agius, J. E., Johnson-Mackinnon, J., Arnott, A., Chandra, S., Gall, M., Draper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2120219 · Cited by 171
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75
Cao, Y., Song, W., Wang, L., Liu, P., Yue, C., Jian, F., Yu, Y., Yisimayi, A., Wang, P., Wang, Y., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.09.018 · Cited by 172
Self-citation
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
Nutalai, R., Zhou, D., Tuekprakhon, A., Ginn, H. M., Supasa, P., Liu, C., Huo, J., Mentzer, A. J., Duyvesteyn, H. M. E., Dijokaite-Guraliuc, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.014 · Cited by 167
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity
Ou, J., Zhou, Z., Dai, R., Zhang, J., Zhao, S., Wu, X., Lan, W., Ren, Y., Cui, L., Lan, Q., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00617-21 · Cited by 169
Self-citation
Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells
Xiong, H., Wu, Y., Cao, J., Yang, R., Liu, Y., Ma, J., Qiao, X., Yao, X., Zhang, B.-H., Zhang, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1815589 · Cited by 155
Self-citation
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1
Jian, F., Wang, J., Yisimayi, A., Song, W., Xu, Y., Chen, X., Niu, X., Yang, S., Yu, Y., Wang, P., et al. (2024) · Nature · doi:10.1038/s41586-024-08315-x · Cited by 169
Self-citation
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A. R., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021) · mBio · doi:10.1128/mbio.00696-21 · Cited by 155
Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
D'Cruz, R. J., Currier, A. W., & Sampson, V. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00468 · Cited by 151
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Custódio, T. F., Das, H., Sheward, D. J., Hanke, L., Pažický, S., Pieprzyk, J., Sorgenfrei, M., Schroer, M. A., Gruzinov, A. Y., Jeffries, C. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19204-y · Cited by 154
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
Liang, J. G., Su, D., Song, T., Zeng, Y., Huang, W., Wu, J., Xu, R., Luo, P., Yang, X., Zhang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21634-1 · Cited by 153
Self-citation
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
He, Q., Mao, Q., An, C., Zhang, J., Gao, F., Bian, L., Li, C., Liang, Z., Xu, M., & Wang, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1902245 · Cited by 152
Self-citation
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
Cao, Y., Jian, F., Zhang, Z., Yisimayi, A., Hao, X., Bao, L., Yuan, F., Yu, Y., Du, S., Wang, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111845 · Cited by 154
Self-citation
A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice
Lu, J., Lu, G., Tan, S., Jia Hui, X. I. A., Xiong, H., Yu, X., Qi, Q., Yu, X., Li, L., Yu, H., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00392-7 · Cited by 147
Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals
Zhang, J., Wu, Q., Liu, Z., Wang, Q., Wu, J., Hu, Y., Bai, T., Xie, T., Huang, M., Wu, T., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00824-5 · Cited by 147
Self-citation
Review of Current COVID-19 Diagnostics and Opportunities for Further Development
Mardian, Y., Kosasih, H., Karyana, M., Neal, A., & Lau, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.615099 · Cited by 153
High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening
Clarke, C., Prendecki, M. F., Dhutia, A., Ali, M. A., Sajjad, H., Shivakumar, O., Lightstone, L., Kelleher, P., Pickering, M. C., Thomas, D., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020060827 · Cited by 145
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
Cao, Y., Yisimayi, A., Bai, Y., Huang, W., Li, X., Zhang, Z., Yuan, T., An, R., Wang, J., Xiao, T., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00514-9 · Cited by 140
Self-citation
Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2
Jang, Y., Shin, H., Lee, M. K., Kwon, O. S., Shin, J. S., Kim, Y., Kim, C. W., Lee, H.-R., & Kim, M. (2021) · Scientific Reports · doi:10.1038/s41598-020-80896-9 · Cited by 136
Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2
Cheng, M. P., Yansouni, C. P., Basta, N. E., Desjardins, M., Kanjilal, S., Paquette, K., Caya, C., Semret, M., Quach, C., Libman, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2854 · Cited by 138
High neutralizing antibody titer in intensive care unit patients with COVID-19
Liu, L., To, K. K., Chan, K., Wong, M. Y.-C., Zhou, R., Kwan, K., Fong, C. H.-Y., Chen, L., Choi, C. Y.-K., Lu, L., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1791738 · Cited by 135
SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus
Dogan, M., Kozhaya, L., Placek, L., Gunter, C., Yiğit, M., Hardy, R., Plassmeyer, M. L., Coatney, P., Lillard, K., Bukhari, Z., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01649-6 · Cited by 126
SARS-CoV-2 infection causes dopaminergic neuron senescence
Chen, S., Kim, T. W., Yang, L., Kim, T., Nair, M., Harschnitz, O., Wang, P., Zhu, J., Koo, S. Y., Tang, X., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2023.12.012 · Cited by 132
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
Yu, Y., Wang, M., Zhang, X., Li, S., Lu, Q., Zeng, H., Hou, H., Li, H., Zhang, M., Jiang, F., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00759-1 · Cited by 122
Self-citation
Comparison of Four SARS-CoV-2 Neutralization Assays
Riepler, L., Rössler, A., Falch, A., Volland, A., Borena, W., von Laer, D., & Kimpel, J. (2020) · Vaccines · doi:10.3390/vaccines9010013 · Cited by 117
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsPreprint
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.30.442182 · Cited by 118
A comparative review of immunoassays for COVID-19 detection
Mohit, E., Rostami, Z., & Vahidi, H. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1908886 · Cited by 120
Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates
Shou, S., Liu, M., Yang, Y., Kang, N., Song, Y., Tan, D., Liu, N., Wang, F., Liu, J., & Xie, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.626553 · Cited by 120
Self-citation
Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
Khoury, D. S., Wheatley, A. K., Ramuta, M. D., Reynaldi, A., Cromer, D., Subbarao, K., O’Connor, D. H., Kent, S. J., & Davenport, M. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00471-1 · Cited by 115
25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor
Zu, S., Deng, Y., Chao Hui, Z. H. O. U., Li, J., Li, L., Chen, Q., Li, X., Zhao, H. J., Gold, S., He, J., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00398-1 · Cited by 116
Self-citation
ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species
Yan, H., Jiao, H., Liu, Q., Zhang, Z., Xiong, Q., Wang, B.-J., Wang, X., Guo, M. S., Wang, L., Lan, K., et al. (2021) · Nature Ecology & Evolution · doi:10.1038/s41559-021-01407-1 · Cited by 121
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
Tada, T., Dcosta, B. M., Samanovic-Golden, M., Herati, R. S., Cornelius, A., Mulligan, M. J., & Landau, N. R. (2021) · doi:10.1101/2021.02.05.430003 · Cited by 153
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses
Hu, Y., Ma, C., Szeto, T., Hurst, B. L., Tarbet, E. B., & Wang, J. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00761 · Cited by 115
Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung OrganoidsPreprint
Han, Y., Yang, L., Duan, X., Duan, F., Nilsson-Payant, B. E., Yaron, T. M., Wang, P., Tang, X., Zhang, T., Zhao, Z., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.05.079095 · Cited by 107
Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification
Li, X., Zhu, W., Fan, M., Zhang, J., Peng, Y., Huang, F., Wang, N., He, L., Zhang, L., Holmdahl, R., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.001 · Cited by 109
Self-citation
Construction and applications of SARS-CoV-2 pseudoviruses: a mini review
Chen, M., & Zhang, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59184 · Cited by 110
A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients
Chen, Y., Tong, X., Li, Y., Gu, B., Yan, J., Liu, Y., Shen, H., Huang, R., & Wu, C. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008796 · Cited by 104
On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies
Mattioli, I. A., Hassan, A., Oliveira, O. N., & Crespilho, F. N. (2020) · ACS Sensors · doi:10.1021/acssensors.0c01382 · Cited by 103

Authors: Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Fan, C., Huang, W., Xu, M., & Wang, Y.
Affiliations: National Institutes for Food and Drug Control (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author: Huang, Weijin
Xu, Miao
Wang, Youchun
ORCID: Nie, Jianhui
Li, Qianqian
Wu, Jiajing
Zhao, Chenyan
Liu, Huan
Zhang, Li
Nie, Lingling
Wang, Meng
Lu, Qiong
Li, Xiaoyu
Sun, Qiyu
Fan, Changfa
Huang, Weijin
Xu, Miao
Wang, Youchun
Venue: Emerging Microbes & Infections
Publisher: Informa UK Limited
Published: 2020-01
Volume: 9
Issue: 1
Pages: 680-686
ISSN: 2222-1751 (ISSN-L)
DOI: 10.1080/22221751.2020.1743767
PMC: PMC7144318
OpenAlex: W3012650581
Cited by: 711
References: 27
Citations by year: 2026: 21 · 2025: 37 · 2024: 73 · 2023: 95 · 2022: 157 · 2021: 186 · 2020: 141
FWCI: 19.06
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Emerging Microbes & Infections (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, pseudovirus neutralization assay, neutralizing antibodies, biosafety level 2, convalescent sera, assay validation, detection limit, cut-off values, COVID-19 treatment
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Animals, Antibodies, Viral, Cell Line, Humans, Immune Sera, Immunization, Passive, Membrane Glycoproteins, Neutralization Tests, Plasmids, Pneumonia, Viral, Sensitivity and Specificity, Vesicular stomatitis Indiana virus, Viral Envelope Proteins, Reproducibility of Results, Coronavirus Infections, Mice, Virus Internalization, Antibodies, Neutralizing, Limit of Detection, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks